Every supplement claim has a supply chain. It runs from the ingredient, to the clinical trial that tests it, to the regulatory file that turns a result into a licensed claim. Capital is now buying that chain. Supplement claim substantiation — the work of proving a product does what it says — is becoming an asset class. One investor has just taken control of two linked businesses. One makes nutraceutical ingredients. The other generates the clinical proof for products like them. The move signals who gets to make claims, what evidence will cost, and whom a buyer can trust.
On June 30, 2026, KGK Science closed a growth investment led by Maxim Partners. KGK, based in London, Ontario, is one of the oldest contract research organizations serving the natural health trade. Founded in 1997, it has run more than 400 clinical trials across over 40 health indications. It has published more than 150 peer-reviewed papers, making its name first in probiotics and later in cannabis science. Founder and CEO Najla Guthrie, who sits on the International Probiotics Association board, stays on. Terms were not disclosed.
The part the announcement left out
The release framed this as a growth investment in a research lab. The more useful fact sits one level up. Maxim Partners has held a majority stake in Stratum Nutrition, a nutraceutical ingredient supplier, since 2022. Stratum sells branded actives, including eggshell-membrane ingredients for joint and skin health, one of which was named a collagen ingredient of the year in 2025. Add KGK, and a single Chicago firm now owns both a company that sells ingredients and one that generates the clinical evidence behind them. Managing Partner Gregg Wilson has been explicit that the plan is to build an acquisitive platform in the sector.
That history sharpens the point. KGK spent most of the past decade owned by companies with little to do with supplements. Auxly Cannabis Group bought it in 2018. Auxly then sold it to Myconic Capital, later Wellbeing Digital Sciences, for $16.5 million in 2021. The Maxim deal moves it back into a nutrition portfolio and pairs it with an ingredient business. This industry’s evidence layer is being consolidated, and on purpose.
Why supplement claim substantiation is now an asset
Consider the economics of supplement claim substantiation. Generating clinical evidence used to be a six-figure undertaking reserved for the largest brands. Decentralized and virtual trials are changing that. Analysts see the decentralized-trial market growing about 14.5 per cent a year, toward roughly US$38 billion by 2035. The model cuts cost by moving data collection out of central sites. KGK has earmarked its new capital for exactly this capability. As the price of a credible study falls, evidence moves from luxury toward baseline.
Demand is rising as supply gets cheaper. Regulators and retailers on both sides of the border are pushing brands toward data they can show. A clean-label market increasingly treats a human trial as the price of a premium claim, not a bonus. When a services market is growing, defensible and tied to tightening rules, investors notice. This deal is one of several signs that the smart money now sees substantiation itself as the product.
The Canadian cost squeeze brands are underpricing
A second force is at work in Canada, and it runs the opposite way from cheaper trials. Health Canada has proposed cost-recovery fees for natural health products. They cover pre-market evaluation, site licences, and an annual right-to-sell charge on every Natural Product Number. The fees were slated to begin on December 1, 2025. They were paused under the federal Red Tape Review and are expected to return alongside the NHP modernization already underway.
The direction of travel matters more than the delay. If a per-NPN annual fee arrives, the cost of simply holding a claim on the market rises for every SKU a brand lists. A long tail of thinly supported products stops being free to keep. The rational response is to concentrate on fewer, better-substantiated lines. That is precisely the behaviour cheaper trials now enable. Falling evidence costs and rising carrying costs point brands toward the same place: prove the winners, retire the rest.
What the trade should do with this
Three consequences follow, and none of them wait for the fee file to reopen.
First, independence becomes a diligence question. When one investor owns both an ingredient supplier and a CRO, the buyer’s homework changes. Anyone weighing a substantiation dossier can fairly ask who ran the study, and who owns them. This is not an accusation against any lab. It is a new box to check as the evidence supply chain consolidates.
Second, the competitive floor is rising. Cheaper trials mean a wave of better-substantiated products is coming. “We could not afford the research” stops being a credible reason a claim rests on a borrowed monograph. Brands that treat clinical work as a core asset will pull ahead of those that treat it as an expense.
Third, retailers gain leverage they have rarely used. As substantiated supply grows, a category manager can make human data a condition of listing, not a nice-to-have. The ask is simple: show the trial, name the CRO, and confirm the claim matches the licensed NPN. The brands ready for that conversation will be the ones that invested before it was demanded. A category long content with assertion is about to be handed both the tools and the reasons to demand proof.
Frequently asked questions
What did KGK Science and Maxim Partners announce?
KGK Science, a London, Ontario contract research organization, closed a growth investment led by Maxim Partners on June 30, 2026. Financial terms were not disclosed. Founder and CEO Najla Guthrie and existing management continue to run the business, with capital directed at clinical capacity, decentralized and virtual trials, and regulatory services.
Why should supplement brands and retailers care about a research-lab deal?
Contract research organizations produce the clinical evidence behind supplement claims. Cheaper decentralized trials are putting real studies within reach of mid-sized brands, so more competitors will arrive with defensible, licensed claims. That raises the competitive floor and lets retailers treat human data as a condition of listing rather than a bonus.
Does one investor owning both KGK and an ingredient supplier raise a concern?
It raises a diligence question, not a verdict. Maxim Partners also holds a majority stake in ingredient supplier Stratum Nutrition, so the same firm now owns an ingredient business and a research lab. Buyers evaluating a substantiation dossier can reasonably ask who conducted a study and who owns that lab.
How do Health Canada’s changing rules factor in?
Health Canada proposed cost-recovery fees for natural health products, including an annual right-to-sell charge per NPN, slated for December 2025 but now paused pending modernization. If they return, holding each claim on the market carries an annual cost, pushing brands toward fewer, better-substantiated products.
This is independent editorial analysis from IHR Magazine. It references KGK Science, Maxim Partners, Stratum Nutrition and related transactions as examples of a broader industry trend, not as an endorsement of any company or service, and implies no wrongdoing by any party. Brands and retailers should verify NPN status and licensed claims before making substantiation, assortment or marketing decisions.
